This randomised trial aims to assess the role of beta1-3 glucan supplementation in improving clinical symptoms and other outcomes amongst hospitalised patients with COVID-19.

开始日期2023-06-01

申办/合作机构-

NCT05079529 / Unknown status临床2期IIT

Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome Based on NCEP-ATP III Criteria With Modification on Obesity Classification (Waist Circumference Measurement) for Asian Population

The aim of this study is to determine the role and efficacy of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) from mycelia extract of Indonesia's Ganoderma lucidum as an antioxidant and anti-inflammatory agent on cardiometabolic syndrome

开始日期2021-06-30

申办/合作机构

Brawijaya University

100 项与 β-1,3/1,6-D-Glucan 相关的临床结果

登录后查看更多信息

100 项与 β-1,3/1,6-D-Glucan 相关的转化医学

登录后查看更多信息

100 项与 β-1,3/1,6-D-Glucan 相关的专利（医药）

登录后查看更多信息

147

项与 β-1,3/1,6-D-Glucan 相关的文献（医药）

2023-11-01·Fish & Shellfish Immunology

Effects of β-1,3-glucan on growth, immune responses, and intestinal microflora of the river prawn (Macrobrachium nipponense) and its resistance against Vibrio parahaemolyticus

Article

作者: Xu, Wenyue ; Zhu, Bihong ; Zhao, Yunlong ; Du, Xinglin ; Tian, Jiangtao ; Li, Yiming ; Yang, Ying ; Huang, Yizhou ; Ye, Yucong

In this study, we investigated the impact of β-1,3-glucan on the immune responses and gut microbiota of the river prawn (Macrobrachium nipponense) in the presence of Vibrio parahaemolyticus stress. Shrimps were fed one of the following diets: control (G1), 0.2% curdlan (G2), 0.1% β-1,3-glucan (G3), 0.2% β-1,3-glucan (G4), or 1.0% β-1,3-glucan (G5) for 6 weeks and then challenged with V. parahaemolyticus for 96 h. Under Vibrio stress, shrimps in G4 exhibited the highest length gain rate, weight gain rate, and survival rate. They also showed increased intestinal muscle thickness and villus thickness compared to the control and 0.2% curdlan groups. The apoptosis rate was lower in G4 than in the control group, and the digestive enzyme activities (pepsin, trypsin, amylase, and lipase), immune enzyme activities (acid phosphatase, alkaline phosphatase, lysozyme, and phenoxidase), and energy metabolism (triglyceride, cholesterol, glycogen, and lactate dehydrogenase) were enhanced. Expression levels of growth-related genes (ecdysone receptor, calmodulin-dependent protein kinase I, chitin synthase, and retinoid X receptor) and immune-related genes (toll-like receptor 3, myeloid differentiation primary response 88, mitogen-activated protein kinase 7, and mitogen-activated protein kinase 14) were higher in G4 than in the control. Microbiota analysis indicated higher bacterial abundance in shrimps fed β-1,3-glucan, as evidenced by Sob, Chao1, and ACE indices. Moreover, 0.2% β-1,3-glucan increased the relative abundances of Bacteroidota and Firmicutes while reducing those of Corynebacteriales and Lactobacillales. In summary, β-1,3-glucan enhances immune enzyme activities, alters immune-related gene expression, and impacts gut microbial diversity in shrimp. These findings provide valuable insights into the mechanisms underlying β-1,3 glucan's immune-enhancing effects.

2023-08-01·Fish & shellfish immunology

Probiotics and Immunostimulant modulate intestinal flora diversity in Reeves' Turtle (Mauremys reevesii) and effects of Clostridium butyricum on its spleen transcriptome.

Article

作者: Luo, Meng ; Feng, Guoqing ; Ke, Hao ; Chen, Mingjie

In this study, we investigated the effects of Clostridium butyricum (group A), Bacillus subtilis (group B), and the immune enhancer algal β-1,3 glucan (group C) on the intestinal flora of Reeves' turtle Mauremys reevesii and the effects of C. butyricum on the transcriptome of M. reevesii splenic immune tissues. Reeve' turtles were assigned to four groups, each containing three replicates from 18 samples. Juvenile turtles with an initial weight of 106.35 ± 0.03 g were fed a basic diet containing no probiotics (group D), or a basic diet containing C. butyricum TF20201120, B.subtilis, or algal β-1,3 glucan supplement, respectively. After the turtles had been fed for 60, 90, and 120 d of the experimental period, high-throughput sequencing of the 16S rRNA gene revealed no significant difference in alpha diversity among the four groups at 60 days of feeding (P > 0.05), and at 90 days, the alpha diversity in group A was significantly different (P < 0.05), with an increase of 26.62% in the Shannon index and a decrease of 83.33% in the Simpson index; at 120 d, the alpha diversity (Shannon index) showed a decreasing trend in order for groups A, B, and C, At the phylum level, the abundance of Bacteroidetes, Proteobacteria, and Fusobacteria in group A increased significantly with increasing feeding time (P < 0.05), At the genus level, the abundance of Ruminococcaceae and Anaerotruncus in group A increased significantly compared with that in the other three groups (P < 0.05). Transcriptome analysis showed that 384 genes were differentially expressed in the spleen of M. reevesii, 195 genes were upregulated and 189 genes were downregulated, and C. butyricum TF201120 regulated the hematopoietic cell lineage signaling pathway in the spleen of M. reevesii (P < 0.05). The regulation of several identified immune-related genes was confirmed by qPCR. These results showed that C. butyricum, B. subtilis, and the immune enhancer algal β-1,3 glucan can improve the intestinal flora of M. reevesii, with C. butyricum TF20201120 being the most effective and significantly enhancing the immunity of M. reevesii.

2023-07-31·Journal of fungi (Basel, Switzerland)

Comparison of β-1-3-D-Glucan and Candida Mannan Biomarker Assays with Serological Tests for the Diagnosis of Candidemia.

Article

作者: Richardson, Malcolm D ; Bakri, Ahmed Rafezzan Bin Ahmed ; Rautemaa-Richardson, Riina ; Eades, Christopher P ; Moore, Caroline B ; Novak-Frazer, Lilyann ; Lau, Jeffrey C Y

Invasive candidiasis, including bloodstream infection (candidemia), encompasses the most severe forms of Candida infection. Several species-specific and non-specific serological assays are commercially available to aid in diagnosis. This study compared the performance of five such biomarker assays. Serum samples from 14 patients with proven or probable invasive candidiasis, and from 10 control patients, were included in the analysis. A total of 50 serum samples were tested using C. albicans germ tube antibody (CAGTA) assay (Vircell), C. albicans IgM, C. albicans IgG and Candida mannan assays (Dynamiker Biotechnology). Among these samples, the β-1-3-D-glucan (BDG) assay (Fungitell), a laboratory standard for the diagnosis of invasive candidiasis, was positive in 20 (40%), intermediate in five (10%) and negative in 25 (50%). In cases of proven or probable candidemia, the sensitivity and specificity of the BDG assay was 86% and 80%, respectively; the Candida mannan assay, 14% and 86%; the CAGTA test, 57% and 60%; the C. albicans IgM assay, 71% and 60%; and C. albicans IgG assay 29% and 90%. In 4/8 (50%) cases with multiple serum samples, C. albicans IgM was positive sooner than BDG. Thus, when used as a rule-out test for invasive candidiasis, our data suggest that the C. albicans IgM assay may assist antifungal stewardship (over serum BDG).

项与 β-1,3/1,6-D-Glucan 相关的新闻（医药）

2023-03-08

·BioSpace

Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society

– Oral presentation to highlightunique results frompre-clinical studies characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on angiogenesis, wound healing and tissue regeneration – EDMONTON, Alberta, March 08, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO;OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the abstract titled “Application of Avena Sativa Derived Therapeutics β-Glucan and Avenanthramide Accelerate Wound Healing in Mice Via Angiogenic and Anti-inflammatory Mechanisms,” has been accepted for a presentation at the Annual Meeting of the Wound Healing Society (WHS) to be held at the National Harbor, MD Conference Center between April 26-29, 2023. The data to be presented springs from the research collaboration between The Angiogenesis Foundation and Ceapro demonstrating that oat-based bioactives beta glucan and avenanthramides have efficacy to reduce scar formation, inhibit inflammation, recruit stem cells, and stimulate angiogenesis. For more information about the conference, please visit the event website here. About the Angiogenesis Foundation & Disclosure The Angiogenesis Foundation was founded in 1994 by a group of physicians, including Dr. William Li who is currently the CEO of the Foundation and a board member of Ceapro Inc. The Foundation is an independent 501(c)(3) scientific organization that drives innovations in health promotion, disease prevention, and disease treatment through research, education, and advocacy. The Foundation has experience in developing rigorous, high-impact scientific studies, including in the vascular and immuno-inflammatory arenas that underlie chronic diseases in oncology, cardiovascular diseases, and wound healing, and has presented its results at national and international meetings, and published in top tier scientific and clinical journals, including Science, Nature, Lancet, and New England Journal of Medicine. For more information or to support the Foundation’s research and programs, visit angio.org. About the Wound Healing Society Founded in 1989, the Wound Healing Society (WHS) is the premier scientific organization focused on wound healing. A nonprofit organization composed of clinical and basic scientists and wound care specialists with a mission to improve wound healing outcomes through science, professional education, and communication. About Ceapro Inc. Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at . For more information contact: Jenene Thomas JTC Team, LLC Investor Relations and Corporate Communications Advisor T (US): +1 (833) 475-8247 E: czo@jtcir.com Issuer: Gilles R. Gagnon, M.Sc., MBA President & CEO T: 780-421-4555 Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

100 项与 β-1,3/1,6-D-Glucan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
代谢综合征	临床2期	印尼	Brawijaya University	2021-06-30
肥胖	临床2期	印尼	Brawijaya University	2021-06-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02402296 (CTgov)	临床4期	侵袭性牙周炎	30	Placebo (Group I (Control Group))	衊夢製憲餘壓蓋醖遞艱(衊觸膚淵製夢鬱選簾積) = 簾憲範鑰選網壓淵窪鏇壓願獵鏇壓鑰鬱選艱衊 (簾繭積遞遞鹹餘憲餘齋, 簾製繭遞蓋網壓衊憲淵 ~ 網鬱鹽艱願憲範鏇醖衊) 更多	-	2015-06-09
				β-1,3/1,6-D-glucan (Group II (Test Group))	衊夢製憲餘壓蓋醖遞艱(衊觸膚淵製夢鬱選簾積) = 製繭範築壓選鏇淵壓衊壓願獵鏇壓鑰鬱選艱衊 (簾繭積遞遞鹹餘憲餘齋, 醖範蓋網醖築構顧餘選 ~ 壓獵簾醖窪鏇鏇糧壓壓) 更多